Cover Image
市場調查報告書

B型肝炎病毒 (HBV) 治療藥 - 全球藥物預測與市場分析

PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 355920
出版日期 內容資訊 英文 323 Pages
訂單完成後即時交付
價格
Back to Top
B型肝炎病毒 (HBV) 治療藥 - 全球藥物預測與市場分析 PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024
出版日期: 2016年01月01日 內容資訊: 英文 323 Pages
簡介

慢性的B型肝炎病毒感染,是由於急性B型肝炎病毒感染時消除病毒失敗引起的嚴重肝疾病。儘管可利用有效的預防疫苗,該疾病仍是全世界的問題,現在,預計全球超過3億5,000萬名患者。全球8大市場的B型肝炎病毒治療藥市場預計從2014年的24億美元到2024年達30億美元,以2.4%的年複合成長率擴大。

本報告提供全球B型肝炎病毒 (HBV) 市場相關調查,B型肝炎病毒概要和治療藥趨勢,未滿足需求,開發平台趨勢,各地區趨勢,今後的預測,及打入市場的主要企業簡介等彙整資料。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因及病理學
  • 症狀
  • 預後
  • 生活品質

第4章 流行病學

  • 疾病的背景
  • 風險因素和合併症
  • 全球的趨勢
  • 預測方法
  • 慢性B型肝炎的流行病學的預測
  • 考察

第5章 疾病的管理

  • 診斷和治療概要
    • 診斷
    • 治療指南主要的處方藥
    • 臨床趨勢
  • 美國
  • 歐洲5個國家
  • 日本
  • 中國

第6章 競爭概要

  • 概要
  • 產品簡介:主力品牌
  • 其他的治療藥物

第7章 未滿足需求和機會

  • 概要
  • 改善長期臨床療效
  • 為了提升認識與提高診斷率的舉措
  • 提高獲得治療的機會
  • 有效標的化、抑制B型肝炎病毒cccDNA的藥物
  • 治療困難患者的安全且有效的治療
  • 克服中國的醫療制度的障礙

第8章 開發平台評估

  • 概要
  • 臨床實驗製圖
  • 臨床開發的潛力藥物
  • 其他開發中的藥物

第9章 現在及未來的加入廠商

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Gilead
    • Bristol-Myers Squibb
    • Roche
    • Merck
    • GSK
    • Novartis
    • Arrowhead Research
    • GlobeImmune

第10章 市場預測

  • 全球市場
  • 美國
  • 歐洲5個國家
  • 日本
  • 中國

第11章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC117PIDR

Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths occurred worldwide.

Available treatment for chronic hepatitis B focuses on viral suppression, and include oral nucleos(t)ide analogues (NAs) and pegylated interferon (PEG-IFN). The two therapy classes have distinctive strengths and weaknesses. Nevertheless, most patients are using long-term NA treatment, and suffer from issues such as high accumulated treatment cost and low compliance.

For the purposes of this report, GlobalData defines the HBV infection therapeutics market to include sales of HBV-specific medication in patients 18 years and older in the eight major pharmaceutical markets (8MM; US, France, Germany, Italy, Spain, UK, Japan, and China). GlobalData expects the market to experience moderate growth that will be primarily driven by the uptake of therapies with novel mechanisms of action (MOAs).

Highlights

Key Questions Answered

  • How good is the management of chronic HBV infection with marketed therapies?
  • Which drugs and players are important in the current management landscape?
  • Which pipeline agents will enter the market during the forecast period (2014-2024)?
  • Will the leading pipeline agents fulfil the unmet needs of current management landscape?
  • What clinical and commercial factors are likely to influence HBV therapeutic uptake in the US, 5EU, Japan and China?

Key Findings

  • GlobalData projects the HBV therapeutics market in the 8MM to grow from approximately $2.4 billion in 2014 to $3.0 billion in 2024, at a compound annual growth rate (CAGR) of 2.4%. This growth across the 8MM will primarily be driven by the launch of pipeline agents, especially those with novel MOAs, while steep generic erosion across the 8MM is expected to curtail market growth over the forecast period.
  • While pipeline agents have the potential to address some of the unmet needs in the HBV treatment landscape, more clinical data are required to demonstrate their advantage over available therapies, according to interviewed KOLs. In addition, these agents are pioneers of novel therapies, which retain substantial room for future development.
  • GlobalData anticipates that opportunities centered on the development of antivirals with novel MOAs, which can improve the efficacy of existing drugs, will exist for current and future players in the HBV therapeutic marketplace for the duration of the forecast period.

Scope

  • Overview of chronic HBV infection, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
  • Topline HBV therapeutics market revenue from 2014-2024. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include strategic competitor assessment, unmet needs, pipeline assessment, and market outlook for the HBV therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global HBV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global HBV therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HBV therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Overview
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology
  • 3.3. Symptoms
  • 3.4. Prognosis
    • 3.4.1. Phases of Chronic HBV Infection
    • 3.4.2. Complications of Chronic Hepatitis B
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast of Chronic Hepatitis B (2014-2024)
    • 4.5.1. Diagnosed Prevalent Cases of Chronic Hepatitis B
    • 4.5.2. Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B
    • 4.5.3. Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B
    • 4.5.4. Age-Standardized Diagnosed Prevalence of Chronic Hepatitis B
    • 4.5.5. Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA Level
    • 4.5.6. Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by ALT Level
    • 4.5.7. Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBeAg Status
    • 4.5.8. Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by Cirrhosis Status
    • 4.5.9. Diagnosed Prevalent Cases of Chronic Hepatitis B with Co-infection of HIV and Hepatitis C
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
    • 5.2.1. Screening and Diagnosis
    • 5.2.2. Clinical Practice
  • 5.3. 5EU
    • 5.3.1. Screening and Diagnosis
    • 5.3.2. Clinical Practice
  • 5.4. Japan
    • 5.4.1. Screening and Diagnosis
    • 5.4.2. Clinical Practice
  • 5.5. China
    • 5.5.1. Screening and Diagnosis
    • 5.5.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands
    • 6.2.1. Baraclude (entecavir)
    • 6.2.2. Viread (tenofovir disoproxil fumarate)
    • 6.2.3. Pegasys (peginterferon alfa-2a)
    • 6.2.4. Hepsera (adefovir dipivoxil)
    • 6.2.5. Tyzeka (telbivudine)
  • 6.3. Other Therapeutics
    • 6.3.1. Conventional and Pegylated Interferon alfa
    • 6.3.2. Nucleos(t)ide Analogs

7. Unmet Needs and Opportunities

  • 7.1. Overview
  • 7.2. Improvements in Long-Term Clinical Outcomes
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Enhanced Public Awareness and Screening Initiatives to Boost Diagnosis Rates
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Increased Access to Treatment
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Drugs That Effectively Target and Suppress HBV cccDNA
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Safe and Efficacious Therapies for Difficult-to-Treat Patients
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity
  • 7.7. Overcome Unique Barriers Posed by China's Healthcare System
    • 7.7.1. Unmet Need
    • 7.7.2. Gap Analysis
    • 7.7.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Phase and Status, Therapy Class, and Location
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Tenofovir Alafenamide Fumarate
    • 8.3.2. ARC-520
    • 8.3.3. GS-9620
    • 8.3.4. GS-4774
  • 8.4. Other Drugs in Development
    • 8.4.1. ABX-203
    • 8.4.2. REP 2139-Ca
    • 8.4.3. Besifovir
    • 8.4.4. Hepabulin
    • 8.4.5. Myrcludex-B
    • 8.4.6. Agents in Early Stages of Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Gilead
    • 9.3.2. Bristol-Myers Squibb
    • 9.3.3. Roche
    • 9.3.4. Merck
    • 9.3.5. GSK
    • 9.3.6. Novartis
    • 9.3.7. Arrowhead Research
    • 9.3.8. GlobeImmune

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. China
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Total Prevalent Cases of Chronic Hepatitis B
    • 11.4.2. Diagnosed Chronic Hepatitis B Patients
    • 11.4.3. Percent Drug-Treated Chronic Hepatitis B Patients
    • 11.4.4. Drugs Included in Each Therapeutic Class
    • 11.4.5. Launch and Patent Expiry Dates
    • 11.4.6. General Pricing Assumptions
    • 11.4.7. Individual Drug Assumptions
    • 11.4.8. Generic Erosion
    • 11.4.9. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologists
    • 11.7.4. Global Director of Therapy Analysis and Epidemiology
    • 11.7.5. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Modes of HBV Transmission
  • Table 2: HBV Serological Markers and Test Interpretations
  • Table 3: Symptoms of HBV Infection
  • Table 4: Phases of Chronic Hepatitis B Infection
  • Table 5: Key Complications of Chronic HBV infection
  • Table 6: Risk Factors and Comorbidities for Chronic Hepatitis B
  • Table 7: 8MM, Sources Used for the Diagnosed Prevalent Cases Forecast of Chronic Hepatitis B
  • Table 8: 8MM, Sources Used for HBV DNA Level
  • Table 9: 8MM, Sources Used for Chronic Hepatitis B by ALT Level
  • Table 10: 8MM, Sources Used for Chronic Hepatitis B HBeAg Status
  • Table 11: 8MM, Sources Used for Cirrhosis Status
  • Table 12: 8MM, Sources Used for HIV Co-infection
  • Table 13: 8MM, Sources Used for Hepatitis C Co-infection
  • Table 14: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B, Both Sexes, All Ages, Select Years, 2014-2024
  • Table 15: 8MM, Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ≥18 Years, N (Row %), 2014
  • Table 16: 8MM, Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ≥18 Years, N, 2014
  • Table 17: US and 5EU, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA, Ages ≥18 Years, N, Both Sexes, 2014
  • Table 18: Japan and China, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA, Ages ≥18 Years, N, Both Sexes, 2014
  • Table 19: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by ALT Level, Ages ≥18 Years, N, Both Sexes, 2014
  • Table 20: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBeAg Status, Ages ≥18 Years, N, Both Sexes, 2014
  • Table 21: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented Cirrhosis Status, Ages ≥18 Years, N, Both Sexes, 2014
  • Table 22: 8MM, Diagnosed Prevalent Chronic Hepatitis B Cases Segmented by Co-infection with HIV and Hepatitis C, Both Sexes, Ages ≥18 Years, N (% of Diagnosed Chronic Hepatitis B Cases), 2014
  • Table 23: Treatment Guidelines for Chronic Hepatitis B
  • Table 24: Most Prescribed Drugs for Chronic Hepatitis B by Class in the 8MM, 2014
  • Table 25: Country Profile - US
  • Table 26: Country Profile - 5EU
  • Table 27: Country Profile - Japan
  • Table 28: Country Profile - China
  • Table 29: Leading Treatments for Chronic Hepatitis B, 2015
  • Table 30: Product Profile - Baraclude
  • Table 31: Antiviral Efficacy of Baraclude Compared with Epivir-HBV
  • Table 32: Antiviral Efficacy of Baraclude in Epivir-HBV-Refractory Patients
  • Table 33: Baraclude SWOT Analysis, 2015
  • Table 34: Global Sales Forecasts ($m) for Baraclude, 2014-2024
  • Table 35: Product Profile - Viread
  • Table 36: Antiviral Efficacy of Viread Compared with Hepsera
  • Table 37: Viread SWOT Analysis, 2015
  • Table 38: Global Sales Forecasts ($m) for Viread, 2014-2024
  • Table 39: Product Profile - Pegasys
  • Table 40: Antiviral Efficacy of Pegasys Monotherapy Compared with Epivir-HBV Monotherapy or the Combination of the Two
  • Table 41: Pegasys SWOT Analysis, 2015
  • Table 42: Global Sales Forecasts ($m) for Pegasys, 2014-2024
  • Table 43: Product Profile - Hepsera
  • Table 44: Antiviral Efficacy of Hepsera in HBeAg-positive patients
  • Table 45: Long-term Antiviral Efficacy of Hepsera in HBeAg-negative patients
  • Table 46: Hepsera SWOT Analysis, 2015
  • Table 47: Global Sales Forecasts ($m) for Hepsera, 2014-2024
  • Table 48: Product Profile - Tyzeka
  • Table 49: Antiviral Efficacy of Tyzeka Compared with Epivir-HBV
  • Table 50: Tyzeka SWOT Analysis, 2015
  • Table 51: Global Sales Forecasts ($m) for Tyzeka, 2014-2024
  • Table 52: Summary of Minor Therapeutics for Chronic HBV Infection, 2015
  • Table 53: Unmet Needs and Opportunities in Chronic HBV Infection
  • Table 54: HBV - Clinical Trials by Phase and Status, 2015
  • Table 55: Key Late-Stage Pipeline Agents for Chronic Hepatitis B Treatment, 2015
  • Table 56: Product Profile - TAF
  • Table 57: TAF SWOT Analysis, 2015
  • Table 58: Global Sales Forecasts ($m) for TAF, 2014-2024
  • Table 59: Product Profile - ARC-520
  • Table 60: Safety of ARC-520 from a Phase I Clinical Trial
  • Table 61: ARC-520 SWOT Analysis, 2015
  • Table 62: Global Sales Forecasts ($m) for ARC-520, 2014-2024
  • Table 63: Product Profile - GS-9620
  • Table 64: GS-9620 SWOT Analysis, 2015
  • Table 65: Global Sales Forecasts ($m) for GS-9620, 2014-2024
  • Table 66: Product Profile - GS-4774
  • Table 67: Phase I Clinical Trial Efficacy Results of GS-4774 in Healthy Participants
  • Table 68: Phase I Clinical Trial Safety Results of GS-4774 in Healthy Participants
  • Table 69: GS-4774 SWOT Analysis, 2015
  • Table 70: Global Sales Forecasts ($m) for GS-4774, 2014-2024
  • Table 71: Other Agents in Clinical Development for Chronic Hepatitis B Treatment, 2015
  • Table 72: Agents in Phase I or early Phase II Clinical Development for Chronic Hepatitis B Treatment, 2015
  • Table 73: Agents in Preclinical Development for Chronic Hepatitis B Treatment, 2015
  • Table 74: Key Companies in the Chronic Hepatitis B Therapeutics Market, 8MM, 2015
  • Table 75: Gilead's Chronic Hepatitis B Portfolio Assessment, 2015
  • Table 76: BMS's Chronic Hepatitis B Portfolio Assessment, 2015
  • Table 77: Roche's Chronic Hepatitis B Portfolio Assessment, 2015
  • Table 78: Merck's Chronic Hepatitis B Portfolio Assessment, 2015
  • Table 79: GSK's Chronic Hepatitis B Portfolio Assessment, 2015
  • Table 80: Novartis' Chronic Hepatitis B Portfolio Assessment, 2015
  • Table 81: Arrowhead's Chronic Hepatitis B Portfolio Assessment, 2015
  • Table 82: GlobeImmune's Chronic Hepatitis B Portfolio Assessment, 2015
  • Table 83: Global Sales Forecasts ($m) for Chronic Hepatitis B Therapeutics, 2014-2024
  • Table 84: Chronic Hepatitis B Therapeutics Market - Drivers and Barriers, 2014-2024
  • Table 85: Sales Forecasts ($m) for Chronic Hepatitis B Therapeutics in the US, 2014-2024
  • Table 86: Key Events Impacting Sales for Chronic Hepatitis B Therapeutics in the US, 2014-2024
  • Table 87: Chronic Hepatitis B Therapeutics Market - Drivers and Barriers in the US, 2014-2024
  • Table 88: Sales Forecasts ($m) for Chronic Hepatitis B Therapeutics in the 5EU, 2014-2024
  • Table 89: Key Events Impacting Sales for Chronic Hepatitis B Therapeutics in the 5EU, 2014-2024
  • Table 90: Chronic Hepatitis B Therapeutics Market - Drivers and Barriers in the 5EU, 2014
  • Table 91: National Healthcare Authorities and Governmental Drug Pricing Authorities in the 5EU
  • Table 92: Sales Forecasts ($m) for Chronic Hepatitis B Therapeutics in Japan, 2014-2024
  • Table 93: Key Events Impacting Sales for Chronic Hepatitis B Therapeutics in Japan, 2014-2024
  • Table 94: Chronic Hepatitis B Therapeutics Market - Drivers and Barriers in Japan, 2014
  • Table 95: Sales Forecasts ($m) for Chronic Hepatitis B Therapeutics in China, 2014-2024
  • Table 96: Key Events Impacting Sales for Chronic Hepatitis B Therapeutics in China, 2014-2024
  • Table 97: Chronic Hepatitis B Therapeutics Market - Drivers and Barriers in China, 2014
  • Table 98: Key Historical and Projected Launch Dates
  • Table 99: Key Historical and Projected Patent Expiry Dates
  • Table 100: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Key Steps in HBV Replication and Potential Therapeutic Targets
  • Figure 2: HBV Structure
  • Figure 3: Prognosis of Chronic HBV infection
  • Figure 4: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B, Both Sexes, Ages ≥18 Years, Select Years, 2014-2024
  • Figure 5: 8MM, Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ≥18 Years, Both Sexes, N, 2014
  • Figure 6: 8MM, Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages ≥18 Years, N, 2014
  • Figure 7: 8MM, Age-Standardised Diagnosed Prevalence of Chronic Hepatitis B, Ages ≥18 Years, 2014
  • Figure 8: Treatment Algorithm for Chronic HBV Infection in Non-cirrhotic, HBeAg-Positive Patients
  • Figure 9: Treatment Algorithm for Chronic HBV Infection in Non-cirrhotic, HBeAg-Negative Patients
  • Figure 10: Chronic hepatitis B Therapeutics - Therapy Class and Trial Location, 2014
  • Figure 11: HBV Phase II/Phase III Pipeline, 2014
  • Figure 12: Competitive Assessment of Late-Stage Pipeline Agents for Chronic Hepatitis B, 2015
  • Figure 13: Clinical and Commercial Positioning of TAF
  • Figure 14: Clinical and Commercial Positioning of ARC-520
  • Figure 15: Clinical and Commercial Positioning of GS-9620
  • Figure 16: Clinical and Commercial Positioning of GS-4774
  • Figure 17: Company Portfolio Gap Analysis in the Chronic Hepatitis B Therapeutic Market, 2014-2024
  • Figure 18: Sales for Chronic Hepatitis B Therapeutics by Country, 2014-2024
  • Figure 19: Sales for Chronic Hepatitis B Therapeutics by Therapy Class, 2014-2024
  • Figure 20: Sales for Chronic Hepatitis B Therapeutics in the US by Therapy Class, 2014-2024
  • Figure 21: Sales for Chronic Hepatitis B Therapeutics in the 5EU by Therapy Class, 2014-2024
  • Figure 22: Sales for Chronic Hepatitis B Therapeutics in Japan by Therapy Class, 2014-2024
  • Figure 23: Sales for Chronic Hepatitis B Therapeutics in China by Therapy Class, 2014-2024
Back to Top